|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DUS4L |
Gene summary for DUS4L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DUS4L | Gene ID | 11062 |
| Gene name | dihydrouridine synthase 4 like | |
| Gene Alias | DUS4 | |
| Cytomap | 7q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0002943 | UniProtAcc | A4D0R5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11062 | DUS4L | LZE24T | Human | Esophagus | ESCC | 7.70e-06 | 1.98e-01 | 0.0596 |
| 11062 | DUS4L | P1T-E | Human | Esophagus | ESCC | 1.13e-08 | 4.33e-01 | 0.0875 |
| 11062 | DUS4L | P2T-E | Human | Esophagus | ESCC | 3.19e-05 | 8.43e-02 | 0.1177 |
| 11062 | DUS4L | P4T-E | Human | Esophagus | ESCC | 1.35e-17 | 3.84e-01 | 0.1323 |
| 11062 | DUS4L | P5T-E | Human | Esophagus | ESCC | 1.48e-02 | 1.48e-01 | 0.1327 |
| 11062 | DUS4L | P8T-E | Human | Esophagus | ESCC | 2.64e-06 | 1.45e-01 | 0.0889 |
| 11062 | DUS4L | P9T-E | Human | Esophagus | ESCC | 1.04e-08 | 2.45e-01 | 0.1131 |
| 11062 | DUS4L | P10T-E | Human | Esophagus | ESCC | 3.82e-06 | 1.51e-01 | 0.116 |
| 11062 | DUS4L | P11T-E | Human | Esophagus | ESCC | 2.55e-03 | 2.51e-01 | 0.1426 |
| 11062 | DUS4L | P12T-E | Human | Esophagus | ESCC | 1.32e-10 | 3.00e-01 | 0.1122 |
| 11062 | DUS4L | P15T-E | Human | Esophagus | ESCC | 9.80e-11 | 2.43e-01 | 0.1149 |
| 11062 | DUS4L | P16T-E | Human | Esophagus | ESCC | 8.96e-04 | 1.63e-01 | 0.1153 |
| 11062 | DUS4L | P17T-E | Human | Esophagus | ESCC | 7.14e-14 | 6.31e-01 | 0.1278 |
| 11062 | DUS4L | P20T-E | Human | Esophagus | ESCC | 1.60e-23 | 5.56e-01 | 0.1124 |
| 11062 | DUS4L | P21T-E | Human | Esophagus | ESCC | 6.95e-16 | 3.31e-01 | 0.1617 |
| 11062 | DUS4L | P22T-E | Human | Esophagus | ESCC | 5.82e-13 | 2.54e-01 | 0.1236 |
| 11062 | DUS4L | P23T-E | Human | Esophagus | ESCC | 2.81e-27 | 7.14e-01 | 0.108 |
| 11062 | DUS4L | P24T-E | Human | Esophagus | ESCC | 2.58e-12 | 2.85e-01 | 0.1287 |
| 11062 | DUS4L | P26T-E | Human | Esophagus | ESCC | 1.35e-12 | 2.84e-01 | 0.1276 |
| 11062 | DUS4L | P27T-E | Human | Esophagus | ESCC | 1.85e-08 | 2.49e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
| GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
| GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DUS4L | SNV | Missense_Mutation | novel | c.212N>T | p.Arg71Ile | p.R71I | O95620 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DUS4L | SNV | Missense_Mutation | c.904T>A | p.Ser302Thr | p.S302T | O95620 | protein_coding | tolerated(0.41) | benign(0.034) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| DUS4L | insertion | In_Frame_Ins | novel | c.906_907insTTACTGGTGCCAAGTGTAGAAAATAGGAAAAATATTTGCACT | p.Ser302_Ser303insLeuLeuValProSerValGluAsnArgLysAsnIleCysThr | p.S302_S303insLLVPSVENRKNICT | O95620 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| DUS4L | deletion | Frame_Shift_Del | novel | c.109delN | p.Tyr37IlefsTer9 | p.Y37Ifs*9 | O95620 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DUS4L | SNV | Missense_Mutation | novel | c.808G>A | p.Glu270Lys | p.E270K | O95620 | protein_coding | tolerated(0.39) | benign(0.117) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| DUS4L | SNV | Missense_Mutation | c.16N>G | p.Met6Val | p.M6V | O95620 | protein_coding | tolerated_low_confidence(0.38) | benign(0) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
| DUS4L | SNV | Missense_Mutation | c.455N>C | p.Gly152Ala | p.G152A | O95620 | protein_coding | tolerated(0.63) | benign(0.027) | TCGA-AG-3894-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| DUS4L | SNV | Missense_Mutation | rs149644587 | c.688N>T | p.Arg230Trp | p.R230W | O95620 | protein_coding | deleterious(0) | possibly_damaging(0.67) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| DUS4L | SNV | Missense_Mutation | c.899N>A | p.Ala300Asp | p.A300D | O95620 | protein_coding | tolerated(0.49) | benign(0.102) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DUS4L | SNV | Missense_Mutation | c.522G>T | p.Lys174Asn | p.K174N | O95620 | protein_coding | tolerated(0.07) | possibly_damaging(0.763) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |